Olanzapine-Induced Weight Gain

Gupta, Sanjay; Droney, Thomas; Al-Samarrai, Sadiq; Keller, Peggy; Frank, Bradford

doi:10.3109/10401239809148817

Cited by 26 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with the data presented by other authors reporting on randomized controlled trials whose figures on weight gain were higher [11.15 kg over 7 months (Gupta et al, 1998); 11.8 kg over 1 year (Nemeroff, 1997)] as well as lower [8.0 kg over 73 weeks (Wirshing et al, 1999); 6.26 kg over 2.54 years ] than ours. Thus, we conclude that weight gain during olanzapine treatment under naturalistic conditions is approximately the same as in randomized controlled trials.…”

Section: Discussionsupporting

confidence: 95%

See 1 more Smart Citation

Weight gain during long-term treatment with olanzapine: a case series

Haberfellner¹,

Rittmannsberger

2004

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The aim of this study was to assess the prevalence of weight gain during long-term treatment with olanzapine under routine conditions. Weight changes in a sample of 27 outpatients with schizophrenic or schizoaffective disorder were assessed over a mean duration of treatment of 22 months (6-42 months). Treatment with olanzapine was started anew or switched from a conventional antipsychotic drug. Eighteen (66.7%) patients gained more than 7% of their initial body weight. Mean weight gain was 9.2 kg over the study period for the first year 7.7 kg, and only 1.7 kg in the second year. Due to some patients losing weight in the second year, the latter finding obscures the fact that more than 50% of patients gained considerable weight also during the second year (4.8 kg). Weight gain per month was significantly higher in patients with lower body mass index, yet the highest weight gain was found in the most obese patient. Weight gain under olanzapine is a serious concern, and should be monitored closely and countered by active measures.

show abstract

Section: Discussionsupporting

confidence: 95%

“…Only some authors present data for periods of more than half a year of olanzapine treatment (Nemeroff, 1997;Gupta et al, 1998;Wirshing et al, 1999;Jones et al, 2001;Kinon et al, 2001). Most of these studies used clinical trial data (Nemeroff, 1997;Wirshing et al, 1999;Jones et al, 2001;Kinon et al, 2001).…”

Section: Introductionmentioning

confidence: 94%

Weight gain during long-term treatment with olanzapine: a case series

Haberfellner¹,

Rittmannsberger

2004

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Obesity is a risk factor for type 2 diabetes, and weight gain is a well-known side effect of olanzapine. 15,16 Our patient' s weight gradually increased while he was taking olanzapine, and this phenomenon has been documented in other case reports. 4,9,17 The gradual, steady increase in weight just before his acute glycemic decompensation occurred may have played a role in its development.…”

Section: Discussionsupporting

confidence: 75%

Dramatic Worsening of Type 2 Diabetes Mellitus Due to Olanzapine After 3 Years of Therapy

Bechara¹,

Goldman²

2001

Pharmacotherapy

View full text Add to dashboard Cite

Olanzapine, a serotonin-dopamine-receptor antagonist, is an atypical antipsychotic agent used to treat schizophrenia and other psychotic disorders. It is preferred over older antipsychotics because of its relatively low frequency of sedation, orthostatic hypotension, extrapyramidal symptoms, and anticholinergic side effects. A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5.9-6.2% to 12.5%. Discontinuation of olanzapine by means of a 3-month taper resulted in a reduction in HbA1c to pretreatment levels. Although cases of olanzapine-induced hyperglycemia have been documented in the literature, this complication has not been reported in a patient maintained on therapy for this duration. Clinicians should be aware of this possible complication in patients receiving long-term olanzapine therapy.

show abstract

“…Eine signifikante Gewichtszunahme tritt vor allem unter der Behandlung mit Clozapin und Olanzapin auf, die hauptsäch-lich durch eine Zunahme der Fettmasse mit gleichzeitigem Anstieg der Leptinspiegel bedingt ist [3,4,5,6]. Die antipsychotische Therapie mit Risperidon, Quetiapin und Amisulprid ist im Allgemeinen mit einer niedrigen bis moderaten Gewichtszunahme verbunden [7,8,9].…”

Section: > Diabetes Mellitus Typ 2 Und Metabolisches Syndrom Treten Bunclassified

Medikamente und Diabetes

Tschoner

Ebenbichler

2009

Diabetologe

View full text Add to dashboard Cite

Olanzapine-Induced Weight Gain

Cited by 26 publications

References 0 publications

Weight gain during long-term treatment with olanzapine: a case series

Weight gain during long-term treatment with olanzapine: a case series

Dramatic Worsening of Type 2 Diabetes Mellitus Due to Olanzapine After 3 Years of Therapy

Medikamente und Diabetes

Contact Info

Product

Resources

About